Cinacalcet + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Hyperparathyroidism
Conditions
Primary Hyperparathyroidism
Trial Timeline
Jun 15, 2000 → Dec 26, 2000
NCT ID
NCT03776058About Cinacalcet + Placebo
Cinacalcet + Placebo is a phase 2 stage product being developed by Amgen for Primary Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT03776058. Target conditions include Primary Hyperparathyroidism.
What happened to similar drugs?
20 of 20 similar drugs in Primary Hyperparathyroidism were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01250405 | Approved | Completed |
| NCT00975221 | Phase 3 | Completed |
| NCT00975000 | Phase 3 | Completed |
| NCT00345839 | Phase 3 | Completed |
| NCT03776058 | Phase 2 | Completed |
| NCT03774771 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Hyperparathyroidism